jCyte, a clinical-stage biotech company, has entered into a licensing agreement with Santen Pharmaceuticals to develop and commercialize its jCell therapy outside the United States.
The deal is valued at up to $252 million, with jCyte receiving $50 million in upfront cash and $12 million in a convertible note offering. The company stands to make an additional $190 million in milestone payments based on regulatory approval and initial sales in Europe, Asia and Japan, according to a press release.
jCell therapy, a first-in-class investigational treatment for retinitis pigmentosa, is a minimally
Uncategorized